1.51

0.66% -0.01

After Hours: 1.51

Vivosim Labs Inc (VIVS)

Overview News Price History Discussions Forecast

Vivosim Labs Inc stock is traded at $1.51, with a volume of 18,714. It is down -0.66% in the last 24 hours and down -16.11% over the past month. VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Previous Close:

$1.52

Open:

$1.5997

24h Volume:

18,714

Relative Volume:

0.01

Market Cap:

$4.37M

Revenue:

$142.00K

Net Income/Loss:

$-1.23M

P/E Ratio:

3.2424

EPS:

0.4657

Net Cash Flow:

$-10.62M

1W Performance:

-4.43%

1M Performance:

-16.11%

6M Performance:

-47.39%

1Y Performance:

+0.00%

1-Day Range:

$1.46

$1.5997

1-Week Range:

$1.43

$1.5997

52-Week Range:

$1.25

$5.30

Vivosim Labs Inc Stock (VIVS) Company Profile

Name

Vivosim Labs Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

858-224-1000

Address

11555 SORRENTO VALLEY ROAD, SAN DIEGO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

VIVS's Discussions on Twitter

Compare VIVS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIVS Vivosim Labs Inc	1.51	4.40M	142.00K	-1.23M	-10.62M	0.4657
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-18	Initiated	H.C. Wainwright	Buy
Nov-10-17	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-25-17	Initiated	Raymond James	Outperform
Aug-11-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Jun-29-15	Initiated	Jefferies	Buy
Jun-29-15	Initiated	Piper Jaffray	Overweight

View All

Vivosim Labs Inc Stock (VIVS) Latest News

Apr 12, 2026

VIVS Technical Analysis & ETF Price Forecast - Intellectia AI

Apr 12, 2026

Apr 08, 2026

Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Apr 08, 2026

Apr 06, 2026

VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart

Apr 04, 2026

Apr 03, 2026

VivoSim Labs Prices Best-Efforts Public Offering - TipRanks

Apr 03, 2026

VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView — Track All Markets

Apr 03, 2026

VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan

Apr 03, 2026

Apr 02, 2026

VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan

Apr 02, 2026

VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm

Apr 02, 2026

Apr 01, 2026

VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia

Apr 01, 2026

VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia

Apr 01, 2026